Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Drug Profile

Etanercept biosimilar - Coherus Biosciences/Daiichi Sankyo

Alternative Names: BAX 2200; CHS-0214

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences; Daiichi Sankyo Company
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2017 Coherus BioSciences enters into a distribution agreement with Orox Pharmaceuticals for etanercept biosimilar in Caribbean (West Indies) and Latin America
  • 03 Nov 2017 Efficacy and adverse event data from the OLSES safety extension trial in Rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 01 Oct 2017 Coherus Biosciences completes a phase III trial for Rheumatoid arthritis (Treatment-experienced) and Plaque psoriasis in United Kingdom, Spain and Germany (SC) (NCT02486939)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top